attenu
measl
vaccin
develop
year
ago
use
throughout
world
recombin
measl
vaccin
candid
develop
express
sever
heterolog
viru
protect
antigen
immunogen
protect
action
confirm
use
experiment
anim
transgen
mice
cotton
rat
primat
recent
develop
measl
vaccinebas
vector
vaccin
candid
review
inform
recombin
measl
vaccin
express
respiratori
syncyti
viru
protein
shown
discuss
measl
viru
member
genu
morbilliviru
famili
paramyxovirida
order
mononegaviral
consist
nucleotid
encod
six
major
structur
protein
nucleoprotein
n
phosphoprotein
p
larg
protein
l
genom
rna
constitut
ribonucleoprotein
complex
rnp
transcript
replic
unit
two
envelop
spike
glycoprotein
hemagglutinin
h
fusion
f
present
surfac
infecti
particl
execut
process
viru
attach
cell
fusion
protein
contribut
viral
assembl
matur
measl
viru
first
isol
ender
peebl
patient
edmonston
strain
propag
human
kidney
alanto
fluid
fibroblast
cell
aikc
measl
vaccin
strain
develop
wildtyp
edmonston
strain
small
plaqu
clone
sheep
kidney
cell
chick
embryon
cell
c
aikc
strain
one
candid
vaccin
strain
expand
programm
immun
epi
overcom
matern
confer
immun
therebi
result
high
seroconvers
rate
young
infant
month
age
million
dose
administ
mainli
japan
seriou
advers
event
report
post
market
surveil
aikc
strain
show
optim
viru
growth
c
small
plaqu
extrem
poor
growth
c
demonstr
temperatur
sensit
ts
biolog
marker
use
valid
vaccin
product
respons
gene
identifi
aikc
vaccin
strain
develop
edmonston
strain
fulllength
sequenc
report
amino
acid
substitut
found
rel
edmonston
wildtyp
recent
develop
molecular
genom
analysi
allow
revers
genet
perform
order
gener
infecti
measl
viru
revers
genet
aikc
vaccin
strain
explor
investig
specif
genom
region
respons
uniqu
biolog
characterist
f
ha
protein
express
experi
reveal
leu
posit
f
protein
respons
format
small
plaqu
vero
cell
phe
posit
f
protein
edmonston
strain
induc
larg
plaqu
vero
cell
infecti
cdna
clone
gener
recombin
viru
induc
small
plaqu
wherea
larg
plaqu
gener
viru
howev
posit
influenc
ts
characterist
replic
transcript
measl
viru
regul
interact
n
p
l
protein
measl
minigenom
system
luciferas
report
gene
insert
measl
leader
trailer
sequenc
develop
investig
transcript
replic
activ
limit
luciferas
activ
observ
p
protein
express
plasmid
aikc
strain
use
minigenom
assay
c
higher
temperatur
wherea
p
express
plasmid
edmonston
strain
influenc
luciferas
activ
c
higher
temperatur
p
protein
aikc
strain
respons
ts
characterist
pro
posit
p
protein
critic
point
ts
phenotyp
base
find
minigenom
assay
use
chimer
p
express
plasmid
construct
aikc
parent
edmonston
strain
recombin
measl
viru
pro
posit
p
protein
gener
show
ts
phenotyp
howev
recombin
measl
viru
leu
posit
p
protein
current
avail
vaccin
categor
two
type
live
attenu
inactiv
vaccin
inactiv
vaccin
princip
induc
humor
antibodi
wherea
humor
cellular
immun
respons
induc
live
attenu
vaccin
therefor
live
attenu
vaccin
clinic
benefit
addit
strong
immun
basic
singl
twodos
immun
provid
longterm
immun
rel
lower
cost
clinic
advers
event
frequent
observ
live
vaccin
inactiv
vaccin
growth
vaccin
strain
bodi
numer
difficulti
associ
develop
new
live
vaccin
convent
procedur
consecut
passag
primari
cell
cultur
immunogen
safeti
profil
confirm
experiment
anim
model
final
avail
establish
largescal
phase
iii
clinic
trial
howev
number
particip
limit
mani
effect
live
attenu
vaccin
known
effect
safe
long
histori
clinic
use
therefor
current
avail
live
vaccinebas
vector
vaccin
also
expect
theoret
safe
immunogen
although
number
recombin
viru
vector
deriv
vaccinia
viru
ankara
strain
poxvirus
adenoassoci
virus
human
parainfluenza
viru
type
iii
develop
viru
vector
deriv
licens
vaccin
strain
without
clinic
experi
predict
biomark
relev
vaccin
safeti
experiment
anim
thu
largescal
clinic
trial
conduct
vector
order
assur
safeti
vector
viru
vector
deriv
current
avail
vaccin
theoret
consid
safe
effect
among
current
licens
vaccin
yellow
fever
vaccin
use
live
attenu
vaccineviru
vector
develop
recombin
japanes
enceph
dengu
west
nile
viru
vaccin
pre
e
region
yellow
fever
vaccin
replac
flavivirus
yellow
fever
vaccinebas
japanes
enceph
viru
vaccin
chimerivaxj
licens
live
attenu
measl
vaccin
popular
yellow
fever
vaccin
induc
effici
humor
cellular
immun
long
clinic
use
guarante
safeti
addit
measl
viru
theoret
replic
cytoplasm
evid
suggest
genom
integr
host
dna
recent
develop
revers
genet
measl
viru
allow
recombin
measl
viru
cdna
artifici
manipul
therebi
contribut
better
understand
mechan
underli
viru
replic
transcript
pathogenesi
live
attenu
measl
vaccin
investig
recombin
viru
vector
besid
yellow
fever
vaccin
sever
strain
avail
throughout
world
attenu
mechan
supposedli
differ
strain
two
group
extens
work
recombin
measl
vaccin
candid
use
licens
measl
vaccin
strain
dr
naim
berna
biotech
dr
tangi
pasteur
institut
other
construct
strategi
target
experiment
model
summar
tabl
target
unmet
need
vaccin
hiv
sar
corona
west
nile
dengu
nipah
chikungunya
hepat
c
virus
convent
strategi
effect
live
inactiv
vaccin
develop
target
target
genom
region
insert
np
pm
hl
junction
popular
insert
site
pm
junction
heterolog
gene
insert
np
junction
amount
mrna
p
gene
decreas
caus
poor
viru
growth
mourez
et
al
report
differ
strategi
f
h
genom
region
measl
viru
replac
chimer
dna
fragment
simian
immunodefici
viru
siv
genom
fuse
cytoplasm
region
measl
f
protein
genom
interact
protein
immunogen
recombin
examin
transgen
mice
express
human
delet
receptor
nonhuman
primat
proper
experiment
anim
evalu
immun
respons
measl
transgen
mice
deplet
ifn
system
appropri
investig
immunogen
follow
administr
recombin
measlesvector
vaccin
candid
preliminari
experi
cotton
rat
sigmodon
hispidu
suscept
measl
viru
infect
measl
viru
genom
detect
region
drain
lymph
node
viru
isol
neutral
antibodi
produc
cotton
rat
three
week
immun
aikc
measl
vaccin
strain
rsv
vaccin
anticip
mani
year
among
mani
unmet
need
vaccin
rsv
one
common
caus
lower
respiratori
tract
infect
infant
young
children
worldwid
peak
age
seriou
rsv
infect
less
month
children
rsv
infect
two
year
age
seriou
complic
report
especi
newborn
babi
born
prematur
lung
diseas
congenit
heart
diseas
rsv
also
caus
lower
respiratori
tract
infect
elderli
immunocompromis
host
well
pediatr
popul
formalininactiv
rsv
vaccin
firsv
develop
discoveri
rsv
howev
fail
induc
protect
immun
result
paradox
tragedi
increas
sever
subsequ
rsv
infect
sinc
mani
challeng
perform
classic
biolog
select
coldadapt
ts
mutant
revers
genet
engin
vaccin
candid
appropri
attenu
subunit
vaccin
fusion
f
glycoprotein
g
provid
longterm
protect
immun
reason
seriou
outcom
firsv
extens
investig
firsv
found
induc
skew
respons
balanc
respons
essenti
develop
rsv
vaccin
therefor
livevector
vaccin
candid
investig
use
human
parainfluenza
bovin
parainfluenza
sendai
virus
measl
vaccinevector
rsv
vaccin
also
report
mok
et
al
report
recombin
measl
viru
cdna
insert
rsv
f
pm
junction
epsteinbarr
eb
viru
protein
hl
junction
infecti
viru
recov
induc
neutral
antibodi
rsv
ebv
experiment
design
construct
recombin
cdna
aikc
strain
immunogen
shown
fig
asc
restrict
enzym
site
introduc
ad
ggcgcg
sequenc
genom
posit
pm
junction
sequenc
ad
clone
vector
construct
nucleotid
posit
sac
ii
site
site
open
read
frame
heterolog
viru
genom
encod
protect
antigen
clone
restrict
enzym
site
nco
introduc
fulllength
infecti
cdna
use
sac
ii
pac
site
transfect
cell
togeth
helper
plasmid
express
measl
n
p
l
protein
control
rna
polymeras
infecti
viru
particl
rescu
blind
passag
vero
cell
c
co
recombin
measl
virus
express
fusion
f
glyco
g
protein
rsv
subgroup
mvaikrsvf
mvaikrsvg
develop
virus
induc
cross
protect
neutral
antibodi
nt
rsv
subgroup
b
cotton
rat
infecti
viru
recov
lung
tissu
cotton
rat
immun
recombin
virus
challeng
rsv
subgroup
protect
effect
suffici
challeng
rsv
subgroup
b
although
detect
rsv
recov
immun
cotton
rat
challeng
mild
inflammatori
pneumon
observ
recombin
measl
virus
express
rsv
np
mvaikrsvnp
gener
togeth
mvaikrsvf
detect
neutral
antibodi
rsv
induc
cotton
rat
immun
recombin
measl
viru
express
np
wherea
high
titer
neutral
antibodi
induc
immun
express
f
g
protein
mvaikrsvnp
induc
strong
ctl
respons
increas
number
cell
spleen
cell
stimul
np
f
peptid
inactiv
rsv
antigen
infecti
viru
recov
lung
homogen
follow
challeng
histolog
examin
lung
tissu
demonstr
signific
reduct
inflammatori
reaction
without
alveolar
damag
despit
neg
neutral
antibodi
neutral
antibodi
ctl
respons
essenti
protect
infect
mitig
inflammatori
respons
consid
clinic
usag
recombin
measl
vaccin
candid
express
rsv
antigen
young
infant
growth
inhibit
vaccin
viru
suppos
matern
confer
immun
cotton
rat
immun
beforehand
differ
dose
aikc
vaccin
strain
signific
antibodi
respons
demonstr
immun
mvaikrsvf
cotton
rat
pa
titer
consid
protect
newborn
young
infant
clinic
set
adult
immun
recombin
viru
mvaikrsvf
would
expect
pregnanc
experiment
model
hardli
develop
differ
immunolog
system
rodent
due
clinic
use
sever
decad
measl
vaccin
consid
safe
immunogen
therebi
provid
longterm
memori
mayb
promis
platform
develop
new
vaccin
sever
issu
remain
resolv
accept
dnaengin
vaccin
public
clinic
guidelin
safeti
profil
regulatori
guidelin
manufactur
vaccin
